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Background: Cervical dilation using mechanical dilators is associated with various complications, such as uterine
perforation, cervical laceration, infections and intraperitoneal hemorrhage. To achieve safe and painless cervical
dilation, we constructed a new medical device to achieve confident mechanical cervical dilation: a continuous
controllable balloon dilator (CCBD).
Methods: Controlled pumping of incompressible fluid into the CCBD increases the pressure and outer diameter of
the CCBD, continuously dilating the cervical canal. The reliability of the CCBD was confirmed in vitro (testing for
consistency and endurance, with no detected risk for breakage) and in vivo. A multi-center clinical study was
conducted,with 120 pregnant women randomly assigned to one of three groups: Group I,control group, no
dilation;Group II,mechanical dilation, Hegar dilator (HeD); and Group III,CCBD. The tissue material for histological
evaluation was obtained from the endocervical mucosa before and after dilation using the HeD or CCBD.
Results: The CCBD dilations were successful and had no complications in all 40 patients of Group III. The cervical
tissue was markedly less damaged after CCBD dilation compared with HeD dilation (epithelium damage: 95% (HeD)
vs. 45% (CCBD), P <0.001; basal membrane damage: 82.5% (HeD) vs. 27.5% (CCBD), P <0.001; stromal damage: 62.5%
(HeD) vs. 37.5% (CCBD), P <0.01). Cervical hemorrhagia was observed in 90% of the patients after HeD dilation
versus in 32.5% of the patients after CCBD dilation.
Conclusions: The CCBD should be used as a replacement for mechanical dilators to prevent uterine and cervical
injury during cervical dilation.
Trial registration: ISRCTN54007498
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Although cervical dilation is most commonly reserved for
childbirth, its use has expanded to a large number of diag-
nostic procedures (dilation and curettage for diagnosing
endometrial cancer, endometrial biopsies, evaluating the
causes of infertility and hysteroscopy) and therapeutic
procedures (cervical stenosis, dysfunctional uterine bleed-
ing and dysmenorrhea, inserting intrauterine devices and
draining the uterine cavity) [1-3]. Mechanical instruments,
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distribution, and reproduction in any mediumdilators, are used to sequentially dilate the cervix [4,5] by
incrementally increasing the diameter of the inserted dila-
tor until the dilation procedure is complete. However,
these mechanical dilators require the use of appropriate
force, which could permanently damage the cervical tissue
and have adverse long-term effects on fertility [6-9]. Their
use is associated with various potential complications,
such as uterine perforation, cervical laceration, infections
and intraperitoneal hemorrhages [4,5,10].
Several lines of evidence have suggested that cervical
priming, accomplished by pharmacological agents (prosta-
glandin analogs), can prevent cervical laceration by redu-
cing the force required for cervical dilation [3,10]. The
main disadvantage of pharmacological agents is that thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the surgical procedure [11-13].
To achieve safe and painless cervical dilation, we con-
structed a medical device for reliable mechanical cervical
dilation: a continuous controllable balloon dilator
(CCBD). The CCBD is based on a patented solution [14]
that combines all of the advantages of traditional mech-
anical devices with several new features that give the
provider full process control in all of the phases of cer-
vical dilation. We conducted a pilot study that showed a
significant reduction in all of the side effects related to
dilator use for the CCBD compared with metal mechan-
ical devices.Methods
Study organization
The study (ISRCTN54007498) was conducted at the
Gynecology & Obstetrics Clinics at Kragujevac Clinical
Center, Serbia, and Podgorica Clinical Center, Monte-
negro. The data were collected by the study coordinators
at the participating centers. The authors vouch for the
completeness and accuracy of the data and analyses. An
independent data and safety monitoring board moni-
tored the study and reviewed the protocol compliance
and outcome data. The protocol was approved by each
participating center's institutional review board.Study patients
The patients were enrolled in the study using the follow-
ing criteria: age between 19 and 40; pregnancy verified
by an ultrasound; singleton pregnancy; gestational
age ≤10; uterus and cervix with normal findings; and ab-
sence of uterine contractions or bleeding.
Patients were excluded from the study if any of the fol-
lowing criteria were met: any signs of spontaneous abor-
tion; any previous attempt at an abortion or use of
substances for cervical maturation; multiple pregnancy;
the presence or, at minimum, the suspicion of a septic
abortion, followed by an elevated body temperature of
38°C or higher, uterine pain and odorous vaginal secre-
tions; the presence of any previous intervention per-
formed on the uterine cervix; uterine or cervical
anomalies; an intrauterine device in situ; or hemorrhagic
and/or chronic diseases.Study design
The study included 120 pregnant women randomly
assigned to one of the following three groups: Group I
(40 pregnant women), control group with no dilations;
Group II (40 pregnant women), dilations performed
using Hegar dilators (HeDs); and Group III (40 pregnant
women), dilations performed using the CCBD.The experiments were undertaken with the under-
standing and appropriate informed consent of each
patient.Continuous controllable balloon dilator: main
characteristics
The CCBD is a fully controllable device for cervical dila-
tion (Figure 1A) based on the use of a specially con-
structed balloon dilator (BD) that consists of three
layers: an inner silicone layer, a central layer made from
high-strength fabric, and an outer silicone layer
(Figure 1B,C). The maximum BD expansion diameter is
limited by the central layer. The outer silicone layer con-
tacts the cervical tissues during dilation. The consistency
and endurance of this BD were tested at a pressure of 25
bars, with no detected risk for breakage. The reliability
of the CCBD was confirmed in vitro and in vivo
(Figure 1D, 1E).
Dilation using the CCBD is performed continuously,
with only one dilator placement. In this study, the CCBD
was integrated into a system that enables real-time data
acquisition and the monitoring of the parameters rele-
vant to the biophysics of dilation (Figure 1A). Dilation
dynamics directly depend on the flow of an incompress-
ible fluid into the BD, which is an easily controllable par-
ameter. Because it is an incompressible working fluid,
distilled water was used with the addition of nonionic
contrast medium (Ultravist-300; Schering AG, Berlin,
Germany), which enabled the visual monitoring of dila-
tion using a digital subtraction apparatus for angiog-
raphy (Figure 1A).
Incompressible fluid from the hydraulic cylinder is
pumped to the BD via a flexible hose (hose) and one-
way valve (Figure 1A). Fluid flow is controlled by an
electric motor that, via a spiral spindles/nut system, pro-
vides constant speed of the hydraulic cylinder piston and
consequently constant fluid flow. The actual position of
the hydraulic cylinder piston and the fluid pressure are
monitored by displacement and pressure transducers.
The unit for measurement and control collects signals
from those two transducers. The pressure gauge is used
for visual control of the current fluid pressure, while the
pressure reduction valve represents a safety element.
After finalization of the dilatation procedure, the choke
valve is opened by remote command, which results in
draining of fluid from the BD. Then the BD could be
easily extracted from the cervical canal. Dilatation dur-
ation and maximum pressure in the BD represents para-
meters assigned by a PC-controlled unit for measurement
and control. Those parameters could be monitored in
real-time parameters by PC and appropriate acquisition
software, which enable full controllability of the cervical
canal dilatation process (Figure 1A).
Figure 1 (See legend on next page.)
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Figure 1 System for continuous controllable balloon dilation. (A)The continuous controllable balloon dilator (CCBD) system for cervical
dilation. (B) Image of the CCBD. (C) CCBD with an uninflated BD (a) and an inflated BD (b). (D) The calculation of cervical resistance during
cervical dilation using the CCBD: line 1, change in pressure during in vitro balloon dilation; line 2, change in pressure during in vivo cervical
dilation using the CCBD; line 3,difference in the change in pressure between the in vivo and in vitro experiments, which represents the resistance
of the cervical tissue to CCBD dilation. (E) Pictures of the phases of in vivo cervical dilation using the CCBD (after 10, 15, 20 and 25 seconds). (F)
The comparative results of CCBD cervical dilations for three representative patients: P1, the cervical resistance of Patient 1 was depressed after
23 seconds with a pressure of 3.8 bars; P2, the cervical resistance of Patient 2 was depressed after 22 seconds with a pressure of 1.4 bars; P3, the
cervical resistance of Patient 3 was depressed after 21 seconds with a pressure of 1.1 bars.
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Tissue material for the histological evaluation of cervical
damage was obtained from the endocervical mucosa by
single curettage (Novac Curette, CooperSurgical, Trum-
bull, Connecticut, USA) before and after dilation using
the HeD or CCBD. The samples were stained with H&E
and blinded analysis was performed using a light micro-
scope (Olympus BX 51; Olympus, Hamburg, Germany).
The surface areas of the hemorrhagic regions were mea-
sured according to a previously published protocol [15].
Statistical analysis
All of the statistical analyses were conducted using SPSS
13.0 for Windows (IBM, New York, New York, USA).
The results were analyzed using Student’s t test. All of
the data in this study are expressed as the mean ± stand-
ard error. P < 0.05 was considered significant.
Results
Continuous controllable balloon dilation results
The CCBD dilations were successfully performed on all
patients. The providers and patients reported no compli-
cations or problems with the CCBD, a new dilation tech-
nique. The average duration of CCBD dilation was
approximately 25.5 seconds (Figure 1F) and was inde-
pendent of the individual patient's cervical resistance
(Figure 1F). The maximal recorded pressure in the BD
during dilation was significantly lower than the test pres-
sure for BD consistency and endurance.
Comparative analysis of biophysical phenomena during
cervical dilation by HeD and CCBD
The basic biophysical models of cervical canal dilation
using the HeD and CCBD are shown in Figure 2. Under
the action of an external force Fe (the force required to di-
late the cervix at each stage of HeD cervical dilation), the
HeD (with diameter Di) moves at speed v through the cer-
vical canal (with length L). The external force Fe must
overcome the resulting sum of the forces that appear in
the direction of the moving HeD. The HeD motion leads
to changes in the geometry of the cervical canal. In vari-
ous ways, the tissue opposes these geometrical changes
upon contact with the HeD, which is characterized by the
pressure distribution p(x). Because a relatively small zoneof the cervical canal is affected by dilation at this time,
high contact loads are produced in the tissue (Figure 2A).
A detailed overview of the basic forces involved in the
contact zones between the HeD and cervical canal tissue
during dilation indicates that only one component of the
applied external force is responsible for dilation. None of
the other forces directly participate in dilation and may
lead to a large number of side effects.
In contrast, the CCBD dilation procedure involves
inserting the BD in its initial form (diameter Di ≈ 4.5 mm)
into the cervical canal, which results in a very low resist-
ance to penetration (Figure 2B). Pumping incompressible
fluid into the BD increases the outer diameter and pres-
sure of the BD, which dilates the cervical canal. Dilation is
performed synchronously along the entire length L of the
cervical canal, where the relative movement between the
tissue/BD contact pair is reduced to almost zero. In this
case, the cervical tissue also opposes changes in its geom-
etry, which is characterized by a much more uniform
pressure distribution p(x) (Figure 2B). All of the compo-
nents of the involved forces participate in dilation, which
significantly reduces any side effects.
Cervical tissue is markedly less damaged and the extent
of cervical hemorrhagia is significantly lower after CCBD
compared with HeD dilation
There was a statistically significant difference in the per-
centage of epithelial damage (P <0.001), basal membrane
damage (P <0,001) and stromal damage (P <0.01) when
comparing cervices dilated by the HeD with cervices
dilated by the CCBD (Figure 3).
In addition, the extent of cervical hemorrhagia was
significantly lower (P <0.01) after CCBD dilation com-
pared with HeD dilation (90% after HeD dilation vs.
32.5% after CCBD dilation; Figure 4).
Discussion
Based on our results, CCBD dilation is a novel, non-in-
vasive, fully controllable and safe clinical procedure; and
compared with the predominant mechanical method for
cervical dilation (HeD) [4], CCBD is a less invasive and
more reliable system for cervical dilation.
The main factors leading to uterine and cervical injury
during dilation procedures that use metal mechanical
Figure 2 Biophysical phenomena during cervical dilations. (A) Biophysical model of Hegar dilator (HeD) dilatation. Under external force
Fe (required to dilate the cervix at each stage of dilation), the dilator of diameter Di moves at speed v through the cervical canal having length
L. Fe must overcome the resultant sum of forces that appeared in the direction of HeD movement. During dilation with the N
09 HeD (diameter
Di = 9 mm) the mean recorded value of external force
―
Fe was 11 N (with vaginal sodium nitroprusside (SNP) gel) and 17 N (with vaginal
misoprostol) [A]. The mean recorded―Fe during dilation with the N
010 HeD (diameter Di = 10 mm)was 13 N [B]. The mean
―
Fe required to
complete cervical canal dilation points to the complex biophysics of processes in the contact zone of tissue and the HeD. HeD motion along the
cervical canal (length L) in the direction of the internal uterine os leads to changes in geometry of the cervical canal. Tissue, in different ways,
opposes this change of geometry in contact with the HeD, characterized by the pressure distribution p(x). (B) Biophysical model of balloon
dilatation (BD) by continuous controllable balloon dilator (CCBD). (a) Initial BD form diameter is approximatelyDi ≈ 4.5 mm,enabling insertion into
the cervical canal with very low resistance to penetration. (b) Pumping of incompressible fluid in the BD leads to increased pressure and outer
diameter of the BD, causing dilatation of the cervical canal. The dilatation process is performed simultaneously on the entire length (L) of the
cervical canal, where relative movement (sliding) between the tissue/BD contact pair is almost reduced to zero. In this case the cervix tissue
opposes less the change in geometry characterized by p(x).
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cavity and/or an anteflexed or retroflexed uterus [13,16-19].
In addition, adolescents have a higher risk for cervical lacer-
ation because they usually have small, physiologically im-
mature cervices that are difficult to dilate [20-22]. AnotherFigure 3 Cervical tissue damage after Hegar dilator and continuous c
cervical epithelial damage. There was a statistically significant difference in
using the Hegar dilator (HeD) and the cervices dilated using the continuou
group, P <0.001. (B) Percentage of patients with cervical basal membrane d
percentage of basal membrane damage between the cervices dilated usin
error, n = 40 per group, P <0.001). (C) Percentage of patients with cervical s
percentage of stromal damage between the cervices dilated using the HeD
n = 40 per group, P < 0.001).significant problem with current cervical dilators is a lack
of control over the rate of dilation – extremely rapid cer-
vical dilation often leads to cervical laceration [23,24].
All of the aforementioned risk factors (the provider's
inexperience, the lack of control over the rate of dilation,ontrollable balloon dilator dilation. (A) Percentage of patients with
the percentage of epithelial damage between the cervices dilated
s controllable balloon dilator (CCBD). Mean ± standard error, n = 40 per
amage. There was a statistically significant difference in the
g the HeD and the cervices dilated using the CCBD. Mean ± standard
tromal damage. There was a statistically significant difference in the
and the cervices dilated using the CCBD. Mean ± standard error,
Figure 4 Extent of cervical hemorrhagia after Hegar dilatorand continuous controllable balloon dilator dilation. (A) A semiquantitative
determination of representative samples. Intraepithelial, subepithelial and stromal bleeding was observed after Hegar dilator (HeD) dilation (a)
compared with intraepithelial hemorrhagia observed after continuous controllable balloon dilator (CCBD) dilation (b). (B) Percentage of patients
with cervical hemorrhagia after HeD and CCBD dilation. A significant difference in the extent of cervical hemorrhagia was observed between the
nondilated and HeD-dilated patients. Mean ± standard error, n = 40 per group, P <0.01. There was no significant difference in the extent of
cervical bleeding observed between the nondilated and CCBD-dilated patients. The extent of cervical hemorrhagia was significantly lower after
CCBD dilation compared with HeD dilation. Mean ± standard error, n = 40 per group, P <0.01.
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could be overcome using the CCBD. Dilation with the
CCBD is fully controllable, safe and independent of the
provider's experience. In the case of incompressible fluid
BD breakage (which did not happen during our study),
the leakage of only a few drops of fluid results in a
sudden pressure drop in the BD; therefore, the risk for
patient injury in this case is almost non-existent. Both
the trainees and the experienced providers could use the
CCBD without the risk for cervical laceration or uterine
perforation. It is noteworthy that CCBD cervical dila-
tion was successfully performed on all of the patients,
regardless of the patient's age, cervical stenosis, uterineposition and previous obstetric history. In addition, no
side effects were observed during the procedure or after
successful cervical dilation. However, it is important to
note that due to limited number of patients enrolled in
this study, a large prospective study should be con-
ducted in order to confirm the effectiveness of CCBD
dilation.Conclusions
We suggest the CCBD as a replacement for mechanical
dilators, with the main purpose of preventing uterine and
cervical injury during cervical dilation. Depending on the
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or in combination with cervical priming agents.
In the end, it should be emphasized that CCBD dilation
is a new, original, non-invasive, fully controllable and safe
technique for cervical dilation. However, because of the
limited number of patients enrolled in this study, a large
prospective study should be conducted in the future to
further confirm the effectiveness of CCBD dilation.
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